Changes in Management After 18F-DCFPyL PSMA PET in Patients Undergoing Postprostatectomy Radiotherapy, with Early Biochemical Response Outcomes

M Ng; M Guerrieri; LM Wong; K Taubman; T Sutherland; A Benson; G Byrne; S Koschel; K Yap; M Starmans; G Ong; C Macleod; M Foo; M Chao

Journal article

Changes in Management After 18F-DCFPyL PSMA PET in Patients Undergoing Postprostatectomy Radiotherapy, with Early Biochemical Response Outcomes

M Ng, M Guerrieri, LM Wong, K Taubman, T Sutherland, A Benson, G Byrne, S Koschel, K Yap, M Starmans, G Ong, C Macleod, M Foo, M Chao

Journal of Nuclear Medicine Official Publication Society of Nuclear Medicine | Published : 2022

DOI: 10.2967/jnumed.121.263521

Abstract

Prostate-specific membrane antigen (PSMA) tracers have increased sensitivity in the detection of prostate cancer, compared with conventional imaging. We assessed the management impact of 18F-DCFPyL PSMA PET/CT in patients with prostate-specific antigen (PSA) recurrence after radical prostatectomy (RP) and report early biochemical response in patients who underwent radiation treatment. Methods: One hundred patients were enrolled into a prospective study, with a prior RP for prostate cancer, a PSA of 0.2-2.0 ng/mL, and no prior treatment. All patients underwent diagnostic CT and PSMA PET/CT, and management intent was completed at 3 time points (original, post-CT, and post-PSMA) and compared. P..

View full abstract

University of Melbourne Researchers

Michael Ng Author

Ming Wong Author

Tom Sutherland Author

Grants

Funding Acknowledgements

The sponsor, GenesisCare, along with Cyclotek (Aust.) Pty. Ltd., provided financial support and access to their good-manufacturing-practice-approved product, <SUP>18</SUP>F-DCFPyL-PSMAradiopharmaceutical. Cyclotek provided support through a project grant from the Department of Industry, Science, Energy, and Resources Cooperative Research Centre Program. No other potential conflict of interest rele-vant to this article was reported.